What next after GDP-based cost-effectiveness thresholds?

Author:

Chi Y-LingORCID,Blecher Mark,Chalkidou Kalipso,Culyer AnthonyORCID,Claxton Karl,Edoka Ijeoma,Glassman Amanda,Kreif NoemiORCID,Jones Iain,Mirelman Andrew J.,Nadjib Mardiati,Morton Alec,Norheim Ole Frithjof,Ochalek Jessica,Prinja Shankar,Ruiz FrancisORCID,Teerawattananon Yot,Vassall Anna,Winch Alexander

Abstract

Public payers around the world are increasingly using cost-effectiveness thresholds (CETs) to assess the value-for-money of an intervention and make coverage decisions. However, there is still much confusion about the meaning and uses of the CET, how it should be calculated, and what constitutes an adequate evidence base for its formulation. One widely referenced and used threshold in the last decade has been the 1-3 GDP per capita, which is often attributed to the Commission on Macroeconomics and  WHO guidelines on Choosing Interventions that are Cost Effective (WHO-CHOICE). For many reasons, however, this threshold has been widely criticised; which has led experts across the world, including the WHO, to discourage its use. This has left a vacuum for policy-makers and technical staff at a time when countries are wanting to move towards Universal Health Coverage. This article seeks to address this gap by offering five practical options for decision-makers in low- and middle-income countries that can be used instead of the 1-3 GDP rule, to combine existing evidence with fair decision-rules or develop locally relevant CETs. It builds on existing literature as well as an engagement with a group of experts and decision-makers working in low, middle and high income countries.

Funder

Rockefeller Foundation

Bill and Melinda Gates Foundation

South African Medical Research Council

Publisher

F1000 Research Ltd

Subject

Public Health, Environmental and Occupational Health,Health Policy,Immunology and Microbiology (miscellaneous),Biochemistry, Genetics and Molecular Biology (miscellaneous),Medicine (miscellaneous)

Reference69 articles.

1. MOH inaugurates Steering and Technical committees for Health Technology Assessment.;C Addo;Ghana News Agency.,2019

2. A one stop shop for cost-effectiveness evidence? Recommendations for improving Disease Control Priorities.;M Arnold;Cost Eff Resour Alloc.,2019

3. The Kenya Gazette.,2018

4. Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness.;R Baltussen;Int J Health Policy Manag.,2016

5. Cost-effectiveness thresholds: pros and cons.;M Bertram;Bull World Health Organ.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3